- Advanced search
- Immuno Portal
- Malaria Portal
|Ligand families/groups||Immune checkpoint modulators|
|Approved drug?||Yes (FDA (2014), EMA (2015))|
|WHO Essential Medicine||WHO Model List of Essential Medicines (21st List, 2019). Access PDF version.|
|International Nonproprietary Names|
|BMS-936558 | MDX-1106 | ONO-4538 | Opdivo®|
|Nivolumab is an IgG4 kappa immunoglobulin that is selective for PD-1, an immune-checkpoint receptor expressed on activated T-cells, monocytes, B-cells, natural killer (NK) T-cells, and dendritic cells . This monoclonal is produced in Chinese hamster ovary cells by recombinant DNA technology. Nivolumab is an immuno-oncology drug.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Sequence analysis of the light and heavy chain variable region peptides of nivolumab shows exact matches with claimed peptide sequences of monoclonal 5C4 contained in patent WO2006121168 .
|GtoPdb PubChem SID||178103907|
|Search PubMed clinical trials||nivolumab|
|Search PubMed titles||nivolumab|
|Search PubMed titles/abstracts||nivolumab|